Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: Safety, pharmacokinetics, and distribution

Toxicology and Applied Pharmacology

Volumn 277, Issue 1, 2014, Pages 49-57

  Vuillemenot, Brian R ^a   Kennedy, Derek ^a   Reed, Randall P ^b   Boyd, Robert B ^b   Butt, Mark T ^c   Musson, Donald G ^a   Keve, Steve ^a   Cahayag, Rhea ^a   Tsuruda, Laurie S ^a   O'Neill, Charles A ^a  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

^b Northern Biomedical Research Inc   (United States)

^c Tox Path Specialists LLC   (United States)

Author keywords

CLN2 disease; Enzyme replacement therapy; Intracerebroventricular; Intrathecal; Neuronal ceroid lipofuscinosis; Tripeptidyl peptidase 1

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; RECOMBINANT ENZYME; RECOMBINANT HUMAN TRIPEPTIDYL PEPTIDASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; AUTOPSY; BODY WEIGHT; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CEREBROSPINAL FLUID; CLINICAL OBSERVATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ENZYME LOCALIZATION; FEMALE; FRONTAL CORTEX; HISTOPATHOLOGY; HUMAN; INFANT DISEASE; INTRACRANIAL PRESSURE; LATERAL BRAIN VENTRICLE; LEUKOCYTE; MACACA FASCICULARIS; MALE; MEDULLA OBLONGATA; MESENCEPHALON; NEURONAL CEROID LIPOFUSCINOSIS; NEURONAL CEROID LIPOFUSCINOSIS LATE INFANTILE TYPE; NONHUMAN; OCCIPITAL CORTEX; SINGLE DRUG DOSE; STEREOTACTIC PROCEDURE; THALAMUS;

CLN2 DISEASE; ENZYME REPLACEMENT THERAPY; INTRACEREBROVENTRICULAR; INTRATHECAL; NEURONAL CEROID LIPOFUSCINOSIS; TRIPEPTIDYL PEPTIDASE-1;

AMINOPEPTIDASES; ANIMALS; CEREBROSPINAL FLUID; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME REPLACEMENT THERAPY; FEMALE; HAPLORHINI; INFUSIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; LEUKOCYTE COUNT; NEURONAL CEROID-LIPOFUSCINOSES; RECOMBINANT PROTEINS; SERINE PROTEASES;

EID: 84897943669     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.03.005     Document Type: Article

References (42)

1. Auclair D., Finnie J., Walkley S.U., White J., Nielsen T., Fuller M., Cheng A., O'Neill C.A., Hopwood J.J. Intrathecal recombinant human 4-sulphatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr. Res. 2012, 71:39-45.
2. Aviezer D., Brill-Almon E., Shaaltiel Y., Hashmueli S., Bartfeld D., Mizrachi S., Liberman Y., Freeman A., Zimran A., Galun E. A plant-derived recombinant human glucocerebrosidase enzyme - a preclinical and phase I investigation. PLoS ONE 2009, 4:e4792.
3. Belichenko P.V., Dickson P.I., Passage M., Jungles S., Mobley W.C., Kakkis E.D. Penetration, diffusion, and uptake of recombinant human alpha-l-iduronidase after intraventricular injection into the rat brain. Mol. Genet. Metab. 2005, 86:141-149.
4. Bessa C., Teixeira C.A., Dias A., Alves M., Rocha S., Lacerda L., Loureiro L., Guimaraes A., Ribeiro M.G. CLN2/TPP1 deficiency: the novel mutation IVS7-10A>G causes intron retention and is associated with a mild disease phenotype. Mol. Genet. Metab. 2008, 93:66-73.
5. Boulton M., Armstrong D., Flessner M., Hay J., Szalai J.P., Johnston M. Raised intracranial pressure increases CSF drainage through arachnoid villi and extracranial lymphatics. Am. J. Physiol. 1998, 275:R889-R896.
6. Bulat M., Klarica M. Recent insights into a new hydrodynamics of the cerebrospinal fluid. Brain Res. Rev. 2011, 65:99-112.
7. Butt M.T. Morphologic changes associated with intrathecal catheters for direct delivery to the central nervous system in preclinical studies. Toxicol. Pathol. 2011, 39:213-219.
8. Chang M., Cooper J.D., Sleat D.E., Cheng S.H., Dodge J.C., Passini M.A., Lobe, l P., Davidson B.L. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 2008, 16:649-656.
9. Deer T.R., Raso L.J., Garten T.G. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication. Pain Med. 2007, 8:259-262.
10. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 2007, 91:61-68.
11. Dittrich F., Ochs G., Grosswe-Wilde A., Berweiler U., Yan Q., Miller J.A., Toyka K.V., Sendtner M. Pharmacokinetics of intrathecally applied BDNF and effects on spinal motoneurons. Exp. Neurol. 1996, 141:225-239.
12. Elleder M., Dvorakova L., Stolnaja L., Vlaskova H., Hulkova H., Druga R., Poupetova H., Kostalova E., Mikulastik J. Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency. Acta Neuropathol. 2008, 116:119-124.
13. Felice B.R., Wright T., Boyd R.B., Butt M.T., Pfeifer R.W., Pan J., Ruiz J.A., Heartlein M.W., Calias P. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys. Toxicol. Pathol. 2011, 39:879-892.
14. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain-barrier to treat brain diseases. Neurobiol. Dis. 2010, 37:48-57.
15. Giedd J.N., Snell J.W., Lange N., Rajapakse J.C., Casey B.J., Kozuch P.L., Vaituzis A.C., Vauss Y.C., Hamburger S.D., Kaysen D., Rapoport J.L. Quantitative magnetic resonance imaging of human brain development: ages 4-18. Cereb. Cortex 1996, 6:551-560.
16. Golabek A.A., Wujek P., Walus M., Bieler S., Soto C., Wisniewski K.E., Kida E. Maturation of human tripeptidyl-peptidase I in vitro. J. Biol. Chem. 2004, 279:31058-31067.
17. Grabb P.A., Albright A.L. Intraventricular vancomycin-induced cerebrospinal fluid eosinophilia: report of two patients. Neurosurgery 1992, 30:630-634.
18. Guhaniyogi J., Sohar I., Das K., Stock A.M., Lobel P. Crystal structure and autoactivation apthway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis. J. Biol. Chem. 2009, 284:3985-3997.
19. Hoederath P., Gautschi O.P., Land M., Hildebrandt G., Fournier J.Y. Formation of two consecutive intrathecal catheter tip granulomas within nine months. Cent. Eur. Neurosurg. 2010, 71:39-42.
20. Hovland D.N., Boyd R.B., Butt M.T., Engelhardt J.A., Moxness M.S., Ma M.H., Emery M.G., Ernst N.B., Reed R.P., Zeller J.R., Gash D.M., Mastermasn D.M., Potter B.M., Cosenza M.E., Lightfoot R.M. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol. Pathol. 2007, 35:676-692.
21. Iannou Y.A., Zeidner K.M., Gordon R.E., Desnick R.J. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 2001, 68:14-25.
22. Jalanko A., Braulke T. Neuronal ceroid lipofuscinoses. Biochim. Biophys. Acta 2009, 1793:697-709.
23. Kishnani P.S., Goldenberg P.C., DeArmey S.L., Heller J., Benjamin D., Young S., Bali D., Smith S.A., Li J.S., Mandel H., Koeberl D., Rosenberg A., Chen Y.T. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. 2011, 99:26-33.
24. Lin L., Lobel P. Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis. Biochem. J. 2001, 357:49-55.
25. Mine S., Sato A., Yamaura A., Tamachi S., Makino H., Tomoika H. Eosinophilia of the cerebrospinal fluid in a case of shunt infection: case report. Neurosurgery 1986, 19:835-836.
26. Munoz-Rojas M.V., Vieira T., Costa R., Fagondes S., John A., Jardim L.B., Vedolin L.M., Raymundo M., Dickson P.I., Kakkis E., Giugliani R. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am. J. Med. Genet. A 2008, 146A:2538-2544.
27. Oyama H., Fujisawa T., Suzuki T., Dunn B.M., Wlodawer A., Oda K. Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2). J. Biochem. 2005, 138:127-134.
28. Pardridge W.M. Peptide Drug Delivery to the Brain 1991, Raven Press, Ltd, New York.
29. Pollay M. The function and structure of the cerebrospinal fluid outflow system. Cerebrospinal Fluid Res. 2010, 7:9.
30. Rubenstein J.L., Fridlyand J., Abrey L., Shen A., Karch J., Wang E., Issa S., Damon L., Prados M., McDermott M., O'Brien J., Haqq C., Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol. 2007, 25:1350-1356.
31. Sandberg D.I., Crandall K.M., Koru-Sengul T., Padgett K.R., Landrum J., Babino D., Petito C.K., Solano J., Gonzalez-Brito M., Kuluz J.W. Pharmacokinetic analysis of etopside distribution after administration directly into the fourth ventricle in a piglet model. J. Neurooncol. 2009, 97:25-32.
32. Shull R.M., Kakkis E.D., McEntee M.F., Kania S.A., Jonas A.J., Neufeld E.F. Enzyme replacement in a canine model of Hurler syndrome. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12937-12941.
33. Sleat D.E., El-Banna M., Sohar I., Kim K.H., Dobrenis K., Walkley S.U., Lobel P. Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 2008, 94:222-233.
34. Sohar I., Sleat D.E., Jadot M., Lobel P. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models. J. Neurochem. 1999, 73:700-711.
35. Sun J.M., Nam M.H., Chung J.Y., Im B., Lee S.Y., Ahn J.S., Park K., Ahn M.J. Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. Cancer Chemother. Pharmacol. 2010, 68:531-538.
36. Van Essen D.C. Surface-based atlases of cerebellar cortex in the human, macaque, and mouse. Ann. N. Y. Acad. Sci. 2002, 978:468-479.
37. Vite C.H., Wang P., Patel R.T., Walton R.M., Walkley S.U., Sellers R.S., Ellinwood N.M., Cheng A.S., White J.T., O'Neill C.A., Haskins M. Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. Mol. Genet. Metab. 2011, 103:268-274.
38. Vuillemenot B.R., Katz M.L., Coates J.R., Kennedy D., Tiger P., Kanazono S., Lobel P., Sohar I., Xu S., Cahayag R., Keve S., Koren E., Bunting S., Tsuruda L.S., O'Neill C.A. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 2011, 104:325-337.
39. Wlodawer A., Durell S.R., Li M., Oyama H., Oda K., Dunn B.M. A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and highly conserved member of the sedolisin family of serine-carboxyl peptidases. BMC Struct. Biol. 2003, 3:8.
40. Yaksh T.L., Rathbun M.L., Dragani J.C., Malkmus S., Bourdeau A.R., Richter P., Powell H., Myers R.R., LeBel C.P. Kinetic and safety studies on intrathecally infused recombinant-methionyl human brain-derived neurotropic factor in dogs. Fundam. Appl. Toxicol. 1997, 38:89-100.
41. Yaksh T.L., Horais K.A., Tozier N., Rathbun M., Richter P., Rossi S., Grafe M., Tong C., Meschter C., Cline J.M., Eisenach J. Intrathecal ketorolac in dogs and rats. Toxicol. Sci. 2004, 80:322-334.
42. Ziegler R.J., Salegio E.A., Dodge J.C., Bringas J., Treleaven C.M., Bercury S.D., Tamsett T.J., Shihabuddin L., Hadaczek P., Fiandaca M., Bankiewicz K., Scheule R.K. Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion. Exp. Neurol. 2011, 23:261-271.